Severe Air Pollution and Increasing Consumption of Tobacco Bolster the Demand for Non-Small Cell Lung Cancer (NSCLC) Therapeutics to Reach $50 billion by 2030

A new report from Industry Experts Inc, on "Non-Small Cell Lung Cancer (NSCLC) Therapeutics," is released. According to this global market research report, the global market for Non-Small Cell Lung Cancer (NSCLC) Therapeutics is estimated at US$27.7 billion in 2024 and is anticipated to record a CAGR of 10.3% during the 2024-2030 analysis period and stand at a projected US$50 billion by 2030.

The Non-Small Cell Lung Cancer (NSCLC) therapeutics market is driven by the increasing rates of tobacco consumption, particularly among younger individuals, and also severe air pollution and poor lifestyle choices. As NSCLC represents 80-85% of all lung cancer cases worldwide, the rising incidence of lung cancer is generating a heightened demand for effective therapies. Key risk factors fueling this trend include exposure to carcinogens from smoking and environmental pollutants, coupled with an aging population that has long been affected by tobacco.

The adenocarcinoma segment is the largest market for non-small cell lung cancer (NSCLC) therapeutics, accounting for 41% in 2024, due to a significant patient base and various treatment options. This cancer type originates in glandular tissue and is often linked to smoking, with the potential to metastasize to multiple organs, contributing to rising incidence and detection rates. The segment's growth is further supported by the availability of targeted therapies for specific genetic alterations, as well as ongoing research into immunotherapy and combination treatment approaches.


The market for non-small cell lung cancer (NSCLC) therapeutics analyzed in this report on a global basis covering all major regions including North America (The United States, Canada, and Mexico), Europe (Germany, France, United Kingdom, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, India, South Korea, and Rest of Asia-Pacific), South America (Brazil, Argentina, and Rest of South America) and Rest of World.

The study analyzes the global market for non-small cell lung cancer (NSCLC) therapeutics analyzed with respect to Cancer Type – Adenocarcinoma, Squamous cell carcinoma (SCC), Large cell carcinoma and Other Cancers (Including Adenosquamous Carcinoma and Sarcomatoid Carcinoma); Therapy Type – Targeted Therapies, Immunotherapy, Chemotherapy, Radiation Therapy and Others (Including Surgery, Photodynamic Therapy (PDT), and Palliative Care); and End-User – Hospitals, Specialty Clinics and Other End-Users (Including Cancer Research Centers, Ambulatory Surgical Centers (ASCs), and Homecare settings).

About Industry Experts, Inc
Industry Experts, Inc., ranks among the leading market research providers globally. The company's off-the-shelf and customized business intelligence reports offer strategic insights and valuable guidance to enable various stakeholders, such as corporate strategists, analysts, researchers and startups, among others, in obtaining valuable, crisp and unbiased current and future market data. For more information, contact us on +1-320-497-3787 or visit https://industry-experts.com/

Comments

Popular posts from this blog

Use of Antimony in Lead Acid Batteries, Flame Retardants Propelling Demand, Projected to Reach US$3.5 billion by 2030

Alzheimer's Drugs Market to Grow Rapidly by about 10% CAGR During 2024-2030 and Touch $5 billion by 2030

Industry Experts, Inc. Projects Global Market for Specialty Cellulose to Reach 2 Million Metric Tons by 2030 Driven by Cellulose Ethers and MCC